Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
With a market cap of 1.06T, Eli Lilly(LLY) trades at $1,126.27. The stock has a price-to-earnings ratio of 40.78 and currently yields dividends of 0.57%.
On 2026-06-16, Eli Lilly(LLY) stock moved within a range of $1,115.50 to $1,146.68. With shares now at $1,126.27, the stock is trading +1.0% above its intraday low and -1.8% below the session's peak.
Trading activity shows a volume of 353.13K, compared to an average daily volume of 3.26M.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.
LLY News
4E Therapeutics, an Austin-based neuroscience company developing treatments for chronic pain, announced that it has been acquired by Eli Lilly (LLY). 4E says it...
Novo Nordisk (NVO) is stepping up its competition with rival Eli Lilly (LLY) in China’s oral weight loss drug market. According to a Reuters report, CEO Mike Do...
Eli Lilly (NYSE:LLY) reported that its non-covalent BTK inhibitor Jaypirca reduced the risk of disease progression or death by 45% in the Phase 3 BRUIN CLL-322...
Analyst ratings
84%
of 32 ratingsMore LLY News
The study found that adding Jaypirca to a time-limited two-year regimen of venetoclax and rituximab reduced the risk of disease progression or death by 45% comp...
Key Points Eli Lilly's growth centers around GLP-1 drugs, but it's also been investing in other healthcare companies. The company's strong earnings put it in...
Eli Lilly (LLY) announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor demonstrated an “encouraging” safety p...
Eli Lilly (LLY) and Company announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, plus v...
Key Points Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors...
Key Points Pharmaceutical giant Eli Lilly's GLP-1 products and new drugs are powering its dividend growth. Parker-Hannifin is a Dividend King that has increas...
Eli Lilly’s (LLY) stock is down about 1% on June 12 as reports surface that some employers are planning to discontinue their coverage of weight-loss drugs. A r...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.